Jan 08, 2024 7:00am EST Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine
Nov 08, 2023 5:30pm EST Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million
Oct 17, 2023 9:15am EDT Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering
Sep 21, 2023 5:00pm EDT Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
